Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology
Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).
Purchase of this product includes a 6-month online access to the data of the reports and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Each of the four reports can be obtained individually, but the package of the four reports provides a 40% discount on the regular prices:
The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).
Purchase of this product includes a 6-month online access to the data of the reports and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Each of the four reports can be obtained individually, but the package of the four reports provides a 40% discount on the regular prices:
- Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016
- Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others
- Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS
- Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?/R, CXCR4, CSF-1R, CD47-SIRP?, Adenosine, STING & Others
- Negative Immune Checkpoints:
- PD-1 (programmed cell death 1
- PD-L1 (programmed cell death ligand 1 (PD-L1)
- CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)
- LAG-3 (Lymphocyte Activation Gene 3; CD223)
- TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)
- VISTA (V-region Ig-containing Suppressor of T-cell Activation) Receptor
- CEACAM1 (Carcino-Embryonic Antigen Cell Adhesion Molecule 1)
- BTLA (B- and T-Lymphocyte Attenuator)
- GARP (Glycoprotein A Repetitions Predominant)
- TIGIT (T-cell Immunoreceptor with Ig and ITIM domains)
- IL-10 (Interleukin-10)
- B7-H3 (CD273)
- Stimulatory Immune Checkpoints:
- CD40 (TNFSFR5)
- GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
- OX40 (CD134; TNFSFR4)
- 4-1BB (CD137; TNFSFR9)
- CD27 (TNFSFR7)
- ICOS (Inducible Co-Stimulator)
- Immunosuppressive tumor microenvironment:
- IDO (Indoleamine 2,3-dioxygenase
- TDO (Tryptophan 2,3 dioxygenase)
- TGF-?/R (Transforming Growth Factor beta/Receptor)
- CXCR4 (Chemokine Receptor Type 4)
- CSF-1R (Colony Stimulating Factor-1 Receptor)
- CD47 – SIRP? (Signal Regulatory Protein Alpha)
- Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
- STING (STimulator of INterferon Genes) Receptor
- Others (e.g. arginase)
The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
REPORT 1:
PD-1 AND PD-L1 IMMUNE CHECKPOINT INHIBITORS 2016
1) PROGRAMMED CELL DEATH 1 (PD-1) RECEPTOR ANTAGONISTS
Specific Anti-PD-1 Antibodies
Bispecific Anti-PD-1 Antibodies
Non-Antibody PD-1 Receptor Antagonists
2) PROGRAMMED CELL DEATH 1 RECEPTOR LIGAND 1 (PD-L1) INHIBITORS
Specific Anti-PD-L1 Antibodies
Bispecific Anti-PD-L1 Antibodies
Non-Antibody PD-L1 Inhibitors
3) CORPORATE PD-1 & PD-L1 IMMUNE CHECKPOINT INHIBITOR R&D PIPELINE
REPORT 2:
INHIBITORS OF NEGATIVE IMMUNE CHECKPOINTS CTLA-4, LAG-3, TIM-3 & OTHERS
1) CTLA-4 ANTAGONISTS
Yervoy (ipilimumab) monotherapy
Yervoy (ipilimumab) combination with Opdivo (nivolumab)
Yervoy (ipilimumab) combination with other therapeutics
Tremelimumab monotherapy
Tremelimumab combination with durvalumab
Tremelimumab combination with other therapeutics
Novel Specific CTLA-4 Antagonists
Novel Bispecific CTLA-4 Antagonists
2) LAG-3 ANTAGONISTS
3) TIM-3 ANTAGONISTS
4) INHIBITORS OF OTHER NEGATIVE IMMUNE CHECKPOINTS
5) CORPORATE IMMUNE CHECKPOINT INHIBITOR R&D PIPELINES
REPORT 3:
COMPETITOR ANALYSIS: ACTIVATORS OF IMMUNE CHECKPOINTS CD40, GITR, OX40, 4-1BB, CD27 & ICOS
1) IMMUNE CHECKPOINT ACTIVATORS
CD40 Agonists
Glucocorticoid-Induced Tumor Necrosis Factor Receptor (GITR) Stimulators
OX40 Agonists
4-1BB (CD137) Agonists
CD27 Agonists
Inducible Co-Stimulator Molecule (ICOS) Agonists
Other Activators
2) CORPORATE IMMUNE CHECKPOINT ACTIVATORS R&D PIPELINE
REPORT 4:
TUMOR MICROENVIRONMENT MODULATION VIA IDO, TGF-?/R, CXCR4, CSF-1R, CD47-SIRP?, ADENOSINE, STING & OTHERS
1) IDO & TDO INHIBITORS
Epacadostat Studies
Indoximod Studies
Novel IDO Inhibitors
Novel TDO Inhibitors
Dual IDO & TDO Inhibitors
2) TGF-BETA/R INHIBITORS
3) CXCR4 ANTAGONISTS & CXCL12 INHIBITORS
4) CSF-1R ANTAGONISTS & CSF-1R TK INHIBITORS
5) CD47 – SIRP? PATHWAY INHIBITION
6) ADENOSINE PATHWAY
Adenosine A2 Receptor (A2AR) Antagonists
CD73 (AMPase) & CD39 (ATP/ADPase) Inhibitors and Adenosine Degradation
7) STING RECEPTOR STIMULATORS
8) OTHER INHIBITORS OF IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT
9) CORPORATE TUMOR MICROENVIRONMENT MODULATOR R&D PIPELINES
PD-1 AND PD-L1 IMMUNE CHECKPOINT INHIBITORS 2016
1) PROGRAMMED CELL DEATH 1 (PD-1) RECEPTOR ANTAGONISTS
Specific Anti-PD-1 Antibodies
Bispecific Anti-PD-1 Antibodies
Non-Antibody PD-1 Receptor Antagonists
2) PROGRAMMED CELL DEATH 1 RECEPTOR LIGAND 1 (PD-L1) INHIBITORS
Specific Anti-PD-L1 Antibodies
Bispecific Anti-PD-L1 Antibodies
Non-Antibody PD-L1 Inhibitors
3) CORPORATE PD-1 & PD-L1 IMMUNE CHECKPOINT INHIBITOR R&D PIPELINE
REPORT 2:
INHIBITORS OF NEGATIVE IMMUNE CHECKPOINTS CTLA-4, LAG-3, TIM-3 & OTHERS
1) CTLA-4 ANTAGONISTS
Yervoy (ipilimumab) monotherapy
Yervoy (ipilimumab) combination with Opdivo (nivolumab)
Yervoy (ipilimumab) combination with other therapeutics
Tremelimumab monotherapy
Tremelimumab combination with durvalumab
Tremelimumab combination with other therapeutics
Novel Specific CTLA-4 Antagonists
Novel Bispecific CTLA-4 Antagonists
2) LAG-3 ANTAGONISTS
3) TIM-3 ANTAGONISTS
4) INHIBITORS OF OTHER NEGATIVE IMMUNE CHECKPOINTS
5) CORPORATE IMMUNE CHECKPOINT INHIBITOR R&D PIPELINES
REPORT 3:
COMPETITOR ANALYSIS: ACTIVATORS OF IMMUNE CHECKPOINTS CD40, GITR, OX40, 4-1BB, CD27 & ICOS
1) IMMUNE CHECKPOINT ACTIVATORS
CD40 Agonists
Glucocorticoid-Induced Tumor Necrosis Factor Receptor (GITR) Stimulators
OX40 Agonists
4-1BB (CD137) Agonists
CD27 Agonists
Inducible Co-Stimulator Molecule (ICOS) Agonists
Other Activators
2) CORPORATE IMMUNE CHECKPOINT ACTIVATORS R&D PIPELINE
REPORT 4:
TUMOR MICROENVIRONMENT MODULATION VIA IDO, TGF-?/R, CXCR4, CSF-1R, CD47-SIRP?, ADENOSINE, STING & OTHERS
1) IDO & TDO INHIBITORS
Epacadostat Studies
Indoximod Studies
Novel IDO Inhibitors
Novel TDO Inhibitors
Dual IDO & TDO Inhibitors
2) TGF-BETA/R INHIBITORS
3) CXCR4 ANTAGONISTS & CXCL12 INHIBITORS
4) CSF-1R ANTAGONISTS & CSF-1R TK INHIBITORS
5) CD47 – SIRP? PATHWAY INHIBITION
6) ADENOSINE PATHWAY
Adenosine A2 Receptor (A2AR) Antagonists
CD73 (AMPase) & CD39 (ATP/ADPase) Inhibitors and Adenosine Degradation
7) STING RECEPTOR STIMULATORS
8) OTHER INHIBITORS OF IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT
9) CORPORATE TUMOR MICROENVIRONMENT MODULATOR R&D PIPELINES
